Precision Oncology Decision Support: Current Approaches and Strategies for the Future
暂无分享,去创建一个
Funda Meric-Bernstam | Gordon B Mills | Elmer V Bernstam | Jia Zeng | Md Abu Shufean | Jordi Rodon | Vijaykumar Holla | Amber M. Johnson | Nora S. Sanchez | Ann M Bailey | Katherine C Kurnit | Ecaterina E Ileana Dumbrava | Beate Litzenburger | Yekaterina B Khotskaya | Amber M Johnson | Timothy A Yap | Nora S Sánchez | John Mendelsohn | Kenna Mills Shaw | Ann M. Bailey | G. Mills | B. Litzenburger | E. Bernstam | F. Meric-Bernstam | K. Kurnit | A. Bailey | Jia Zeng | Y. Khotskaya | V. Holla | J. Mendelsohn | K. Shaw | T. Yap | E. Dumbrava | J. Rodón | Vijaykumar Holla
[1] Charles Swanton,et al. Translational Implications of Tumor Heterogeneity , 2015, Clinical Cancer Research.
[2] Patients with NTRK Fusions Respond to Targeted Therapies. , 2016, Cancer discovery.
[3] V A Memoli,et al. Soluble normal and mutated DNA sequences from single-copy genes in human blood. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[4] Nikhil Wagle,et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. , 2012, Cancer discovery.
[5] S. Gabriel,et al. Advances in understanding cancer genomes through second-generation sequencing , 2010, Nature Reviews Genetics.
[6] S Toikkanen,et al. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Razelle Kurzrock,et al. Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center. , 2015, Journal of oncology practice.
[8] Jorma Isola,et al. Preservation of nucleic acids and tissue morphology in paraffin-embedded clinical samples: comparison of five molecular fixatives , 2013, Journal of Clinical Pathology.
[9] Gert Jan van der Wilt,et al. Is the $1000 Genome as Near as We Think? A Cost Analysis of Next-Generation Sequencing. , 2016, Clinical chemistry.
[10] Funda Meric-Bernstam,et al. Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer , 2014, Molecular Cancer Therapeutics.
[11] Michael Pawlak,et al. Multiple Protein Analysis of Formalin-fixed and Paraffin-embedded Tissue Samples with Reverse phase Protein Arrays , 2013, Molecular & Cellular Proteomics.
[12] J. Troge,et al. Tumour evolution inferred by single-cell sequencing , 2011, Nature.
[13] Dara L Aisner,et al. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. , 2015, Cancer discovery.
[14] Jerry Younger,et al. Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital , 2016, The oncologist.
[15] Kenna R Mills Shaw,et al. Clinical Use of Precision Oncology Decision Support. , 2017, JCO precision oncology.
[16] Md Abu Shufean,et al. "Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource. , 2017, Cancer research.
[17] Richard B. Schwab,et al. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay , 2016, Oncotarget.
[18] Raymond K. Auerbach,et al. The real cost of sequencing: higher than you think! , 2011, Genome Biology.
[19] John R Yates,et al. Mass spectrometry in high-throughput proteomics: ready for the big time , 2010, Nature Methods.
[20] Lee T. Sam,et al. Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.
[21] J. Doroshow,et al. Molecular analysis for therapy choice: NCI MATCH. , 2014, Seminars in oncology.
[22] Funda Meric-Bernstam,et al. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Yingdong Zhao,et al. GeneMed: An Informatics Hub for the Coordination of Next-Generation Sequencing Studies that Support Precision Oncology Clinical Trials , 2015, Cancer informatics.
[24] Prahlad T. Ram,et al. A pan-cancer proteomic perspective on The Cancer Genome Atlas , 2014, Nature Communications.
[25] Funda Meric-Bernstam,et al. The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. , 2015, Drug discovery today.
[26] Marilyn M. Li,et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.
[27] Gregory J Tsongalis,et al. Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center. , 2015, The oncologist.
[28] S. Domchek,et al. Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions. , 2017, Cancer discovery.
[29] Laurent Arnould,et al. Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer , 2016, Oncotarget.
[30] Edward S. Kim,et al. Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. , 2019, JCO precision oncology.
[31] Jane C Weeks,et al. Physicians' attitudes about multiplex tumor genomic testing. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Gad Getz,et al. Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. , 2017, Cancer discovery.
[33] Caroline McNeil,et al. NCI-MATCH launch highlights new trial design in precision-medicine era. , 2015, Journal of the National Cancer Institute.
[34] Funda Meric-Bernstam,et al. Building a personalized medicine infrastructure at a major cancer center. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Renato Martins,et al. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. , 2014, The Journal of molecular diagnostics : JMD.
[36] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[37] Michelle L. McGowan,et al. “A rising tide lifts all boats”: establishing a multidisciplinary genomic tumor board for breast cancer patients with advanced disease , 2016, BMC Medical Genomics.
[38] Funda Meric-Bernstam,et al. Cancer Positive Breast − in Pretreated Advanced Estrogen Receptor Mutations α Emergence of Constitutively Active Estrogen Receptor-Updated , 2014 .
[39] Vladimir Vacic,et al. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. , 2015, JAMA oncology.
[40] Yasushi Totoki,et al. KIF5B-RET fusions in lung adenocarcinoma , 2012, Nature Medicine.
[41] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[42] Robert S Mannel,et al. Initiation of a formalized precision medicine program in gynecologic oncology. , 2016, Gynecologic oncology.
[43] Doron Lipson,et al. Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer , 2016, Clinical Cancer Research.
[44] Donavan T. Cheng,et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.
[45] William Pao,et al. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.
[46] Jeong Eon Lee,et al. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer , 2017, Nature Communications.
[47] Gary W Procop,et al. Prospective Clinical Study of Precision Oncology in Solid Tumors. , 2015, Journal of the National Cancer Institute.
[48] Howard Kaufman,et al. Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers , 2016, The oncologist.
[49] Ken Chen,et al. Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. , 2014, Discovery medicine.
[50] Juan Wisnivesky,et al. Geographic accessibility to clinical trials for advanced cancer in the United States. , 2015, JAMA internal medicine.
[51] Lee T. Sam,et al. Transcriptome Sequencing to Detect Gene Fusions in Cancer , 2009, Nature.
[52] Razelle Kurzrock,et al. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate , 2017, Clinical Cancer Research.
[53] Pierre Validire,et al. Assessment of Whole Genome Amplification for Sequence Capture and Massively Parallel Sequencing , 2014, PloS one.
[54] Nicolas Servant,et al. Functional mutational analysis to assess the oncogenic activity of variant of uncertain significance (VUS) detected in patients included in the SHIVA trial , 2016 .
[55] Yuan Qi,et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] Kathryn A Phillips,et al. Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.
[57] Donavan T. Cheng,et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.
[58] Arul M Chinnaiyan,et al. Translating cancer genomes and transcriptomes for precision oncology , 2016, CA: a cancer journal for clinicians.
[59] Dennis C. Friedrich,et al. Whole-exome sequencing and clinical interpretation of formalin-fixed , paraffin-embedded tumor samples to guide precision cancer medicine , 2014 .
[60] William Pao,et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.
[61] G. Plitas,et al. Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer. , 2016, Immunity.
[62] Ariel Birnbaum,et al. Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program. , 2016, Journal of oncology practice.
[63] Howard L. McLeod,et al. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience. , 2017, The oncologist.
[64] Aleksandar Sekulic,et al. Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non–V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team , 2015, Molecular Cancer Therapeutics.
[65] Benjamin S. Glicksberg,et al. Development and clinical application of an integrative genomic approach to personalized cancer therapy , 2016, Genome Medicine.
[66] Jeffrey W. Clark,et al. Crizotinib in ROS 1-Rearranged Non – Small-Cell Lung Cancer , 2014 .
[67] Peiyong Jiang,et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. , 2013, Clinical chemistry.
[68] F. Cappuzzo,et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.
[69] E. Mardis,et al. Prioritizing targets for precision cancer medicine. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[70] Peter Horak,et al. Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls , 2016, ESMO Open.
[71] R. Schilsky,et al. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[72] M. Ladanyi,et al. Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib , 2006, Clinical Cancer Research.